Skip to main content
letter
. 2023 Jun 6;10:20499361231178625. doi: 10.1177/20499361231178625

Table 5.

Summary of published studies on OPAT in Brazil.

Author City Healthcare system Number of patients OPAT venue Main infections diagnoses Main drugs used in OPAT Conclusions of the study
Oliveira et al. 9 São Paulo SUS 116 Primary care facilities, day hospital Chronic osteomyelitis, acute osteomyelitis, soft tissue infection Teicoplanin, ertapenem, tigecycline 450 primary care health professionals were trained to manipulate catheters and monitor patients. Positive clinical outcomes, with only 3 OPAT-related adverse events. In 1 year, it was possible to redirect 11,698 bed-days to patients in need of orthopedic hospitalization
Psaltikidis et al. 14 Campinas SUS 39 Day hospital Central nervous system syphilis, urinary tract infection, osteomyelitis Ceftriaxone, amikacin, meropenem Favorable clinical outcomes, with improved perception of quality of life by patients. OPAT allowed 1112 days less hospitalization and proved to be cost-effective compared with inpatient treatment
Cassettari et al. 11 São Paulo PHI 441 Home care Urinary tract infection, pulmonary infection, surgical site infection Teicoplanin, ceftriaxone, meropenem Low rate of treatment failure (0.4%). Outpatient stewardship program was effective and safe
Salles et al. 12 Santo André PHI 276 Home care, outpatient clinics Pneumonia, urinary tract infection Ceftriaxone Palliative care and not having had a postdischarge physician office visit within the first 30 days after inclusion in the OPAT program were risk factors for hospital readmission and mortality
Loesch et al. 10 Curitiba SUS 291 Day hospital, home care Urinary tract infection, pneumonia, osteomyelitis Not mentioned OPAT allowed for significant cost savings and reduction in length of stay. OPAT also reduced risk. OPAT also reduced the risk of contamination of patients with multidrug-resistant bacteria
Freitas et al. 13 Fortaleza SUS 23 Day hospital Urinary tract infection, bloodstream infection Ertapenem (only) 95.65% clinical cure among patients with liver and kidney transplants and infections with Gram-negative bacilli susceptible only to carbapenems. Cost of treatment in OPAT was higher than that of hospitalization due to the high price of ertapenem (reference drug) compared with meropenem (generic drug)

OPAT, outpatient parenteral antimicrobial therapy; PHI, private health insurance; SUS, Sistema Único de Saúde (Brazilian public health system).